 |
14 Diseases |  |
6 Trials |
|
6 Trials |  |
245 News |  |
| «1234 |
- | Alhemo (concizumab) / Novo Nordisk
Trial completion date: explorer (clinicaltrials.gov) - Sep 11, 2018
P2, N=33, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Aug 2019 --> Mar 2020
- | Alhemo (concizumab) / Novo Nordisk
Enrollment closed: explorer (clinicaltrials.gov) - Mar 29, 2018
P2, N=26, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Aug 2019 --> Mar 2020 Recruiting --> Active, not recruiting
- | Alhemo (concizumab) / Novo Nordisk
Enrollment closed: explorer (clinicaltrials.gov) - Jan 16, 2018
P2, N=33, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Alhemo (concizumab) / Novo Nordisk
Enrollment open: explorer (clinicaltrials.gov) - Aug 22, 2017
P2, N=33, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Alhemo (concizumab) / Novo Nordisk
Enrollment open: explorer (clinicaltrials.gov) - Aug 15, 2017
P2, N=26, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Alhemo (concizumab) / Novo Nordisk
New P2 trial: explorer (clinicaltrials.gov) - Jun 22, 2017
P2, N=26, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Alhemo (concizumab) / Novo Nordisk
New P2 trial: explorer (clinicaltrials.gov) - Jun 22, 2017
P2, N=33, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Alhemo (concizumab) / Novo Nordisk
Trial completion, Enrollment change: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (clinicaltrials.gov) - Nov 2, 2016
P1, N=24, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=45 --> 24
- Alhemo (concizumab) / Novo Nordisk
Enrollment closed: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (clinicaltrials.gov) - Oct 21, 2016
P1, N=45, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | N=45 --> 24 Recruiting --> Active, not recruiting
- Alhemo (concizumab) / Novo Nordisk
Trial primary completion date: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (clinicaltrials.gov) - Oct 20, 2016
P1, N=45, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2017 --> Oct 2016
- Alhemo (concizumab) / Novo Nordisk
Trial primary completion date: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (clinicaltrials.gov) - Feb 10, 2016
P1, N=45, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Mar 2017 --> Oct 2016 Trial primary completion date: Jul 2017 --> Jan 2017
- Alhemo (concizumab) / Novo Nordisk
Enrollment open: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (clinicaltrials.gov) - Sep 16, 2015
P1, N=45, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jul 2017 --> Jan 2017 Not yet recruiting --> Recruiting
- Alhemo (concizumab) / Novo Nordisk
New P1 trial: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (clinicaltrials.gov) - Jul 8, 2015
P1, N=45, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Alhemo (concizumab) / Novo Nordisk
Trial termination: A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (clinicaltrials.gov) - Jan 7, 2014
P1, N=4, Terminated, Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Suspended --> Terminated; See detailed description
- Alhemo (concizumab) / Novo Nordisk
Enrollment change: A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (clinicaltrials.gov) - Jan 7, 2014
P1, N=4, Terminated, Sponsor: Novo Nordisk
Suspended --> Terminated; See detailed description N=12 --> 4
- ||| Alhemo (concizumab) / Novo Nordisk
Trial completion: Explorer 1: Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (clinicaltrials.gov) - Sep 11, 2012
P1, N=52, Completed, Sponsor: Novo Nordisk
N=12 --> 4 Active, not recruiting --> Completed
- Alhemo (concizumab) / Novo Nordisk
New P1 trial: A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (clinicaltrials.gov) - Jun 27, 2012
P1, N=4, Terminated, Sponsor: Novo Nordisk
- Alhemo (concizumab) / Novo Nordisk
Trial completion: Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects (clinicaltrials.gov) - May 9, 2012
P1, N=8, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Alhemo (concizumab) / Novo Nordisk
New P1 trial: Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects (clinicaltrials.gov) - Mar 13, 2012
P1, N=8, Completed, Sponsor: Novo Nordisk